KLK9

Human kallikrein-related peptidase 9 (KLK9) is a secreted serine protease involved in diverse proteolytic processes^[1]. KLK9 exhibits tissue-specific expression, with high levels detected in skin, brain, and reproductive tissues, suggesting roles in extracellular matrix remodeling and protein activation cascades^[1]. Mechanistically, KLK9 shows low hydrolytic activity toward pro-KLK substrates, distinguishing it from other isoforms such as KLK15, which actively participates in downstream pro-KLK activation^[2]. In disease models, KLK9 expression is upregulated in traumatic spinal cord injury and contributes to neuron degeneration, highlighting its relevance in neurodegenerative processes^[3]. In cancer contexts, KLK9 alternative splice variants are observed across multiple tumor cell lines, indicating potential as diagnostic or prognostic biomarkers^[4][5]. Compared with related isoforms, KLK9 lacks conventional kallikrein loops present in KLK1-3 and displays unique substrate preferences and limited cascade participation^[1][6]. Pharmacological modulation of KLK9 remains largely unexplored; however, analogous studies of KLK isoforms suggest that selective inhibitors or activity-based probes could provide tools for functional studies or therapeutic interventions^[7][8]. Therefore, KLK9 represents a biologically distinct member of the KLK family with specific tissue localization, mechanistic constraints, and potential clinical utility in neurodegeneration and oncology research.